Age
Item
1. male and female participants aged 18 years or over.
boolean
C0001779 (UMLS CUI [1])
Coronary Artery Disease | Atrial Fibrillation | Free of Exclusion Criteria
Item
2. patients diagnosed with cad or af and free of exclusion criteria below.
boolean
C1956346 (UMLS CUI [1])
C0004238 (UMLS CUI [2])
C0332296 (UMLS CUI [3,1])
C0680251 (UMLS CUI [3,2])
Tobacco use Absent
Item
3. not actively using tobacco products (due to vasoactive and pro-aggregatory effects of nicotine).
boolean
C0543414 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
Comprehension Informed Consent | Informed Consent
Item
4. the participant is willing and able to understand the subject information sheet and provide informed consent.
boolean
C0162340 (UMLS CUI [1,1])
C0021430 (UMLS CUI [1,2])
C0021430 (UMLS CUI [2])
Agreement Blood samples taking
Item
5. the participant must agree to comply with the drawing of blood samples for the assessments.
boolean
C0680240 (UMLS CUI [1,1])
C0190979 (UMLS CUI [1,2])
Age
Item
1. male and female participants aged < 18 years of age.
boolean
C0001779 (UMLS CUI [1])
Renal Insufficiency | Estimated Glomerular Filtration Rate
Item
2. patients with impaired renal function egfr <30 ml/min (since renal failure is associated with platelet function defect that may confound results).
boolean
C1565489 (UMLS CUI [1])
C3811844 (UMLS CUI [2])
Nervous system disorder | Liver disease | Kidney Disease | Endocrine System Diseases | Cardiovascular Disease | Gastrointestinal Disease | Lung disease | Hemorrhagic Disorder | Metabolic Disease | Disease Interferes with Protocol Compliance
Item
3. the participant has, in the opinion of the investigator, significant neurological, hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, haemorrhagic metabolic or other disease likely to confound the study requirements or analyses.
boolean
C0027765 (UMLS CUI [1])
C0023895 (UMLS CUI [2])
C0022658 (UMLS CUI [3])
C0014130 (UMLS CUI [4])
C0007222 (UMLS CUI [5])
C0017178 (UMLS CUI [6])
C0024115 (UMLS CUI [7])
C0019087 (UMLS CUI [8])
C0025517 (UMLS CUI [9])
C0012634 (UMLS CUI [10,1])
C0521102 (UMLS CUI [10,2])
C0525058 (UMLS CUI [10,3])
Substance Use Disorders | Mental disorders
Item
4. the participant has a gives a history of substance abuse or demonstrates signs or clinical features of active substance abuse or psychiatric disease.
boolean
C0038586 (UMLS CUI [1])
C0004936 (UMLS CUI [2])
Alcohol intake above recommended sensible limits | Alcohol units/week | Gender
Item
5. alcohol consumption above recommended safe levels (i.e. more than 21 units per week for males, or more than 14 units per week for females) due to the potential effects of high alcohol levels on platelet reactivity.
boolean
C0560219 (UMLS CUI [1])
C0560579 (UMLS CUI [2])
C0079399 (UMLS CUI [3])
Illness Significant Recently
Item
6. any illness deemed significant by the investigator during the four (4) weeks preceding the screening period of the study.
boolean
C0221423 (UMLS CUI [1,1])
C0750502 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,3])
Bleeding tendency Major | Hematological Disease | Platelet Count measurement | Hemoglobin measurement | International Normalized Ratio | Activated Partial Thromboplastin Time measurement | White Blood Cell Count procedure | Neutrophil count
Item
7. any major bleeding diathesis or blood dyscrasia (platelets < 70 x 109/l, hb <8 g/dl, inr>1.4, aptt> x 2unl, leucocyte count< 3.5x 109/l, neutrophil count < 1x 109/l)
boolean
C1458140 (UMLS CUI [1,1])
C0205164 (UMLS CUI [1,2])
C0018939 (UMLS CUI [2])
C0032181 (UMLS CUI [3])
C0518015 (UMLS CUI [4])
C0525032 (UMLS CUI [5])
C0030605 (UMLS CUI [6])
C0023508 (UMLS CUI [7])
C0200633 (UMLS CUI [8])
Study Subject Participation Status | Investigational Medical Device | Investigational New Drugs
Item
8. currently enrolled in an investigational device or drug trial.
boolean
C2348568 (UMLS CUI [1])
C2346570 (UMLS CUI [2])
C0013230 (UMLS CUI [3])